GlassScriptPhysician profile
Bryce Kay Warr
NPI 1114453826
$2,114.77
in general payments reported to CMS, 2019-2025
26 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $37.28 · 2021: $307 · 2022: $358 · 2023: $453 · 2024: $337 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,164.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $820.27 | 2021-2025 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $271.00 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $249.90 | 2019-2025 | Evenity, Prolia |
| Pfizer INC. | $154.44 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.69 | 2021-2023 | Jardiance, Tradjenta |
| Lilly USA, LLC | $67.63 | 2020-2025 | Mounjaro, Zepbound |
| Biohaven Pharmaceutical Holding Company LTD. | $46.17 | 2022 | |
| Novo Nordisk INC | $42.91 | 2021-2025 | Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.59 | 2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $41.31 | 2023-2024 | Quviviq |
| Inspire Medical Systems, INC. | $33.49 | 2023-2025 | Inspire |
| Axsome Therapeutics, INC. | $33.26 | 2024-2025 | Sunosi |
| Edwards Lifesciences Corporation | $25.48 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Livanova USA, INC. | $22.18 | 2022 | |
| Nestle Healthcare Nutrition INC. | $19.53 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $17.52 | 2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $16.53 | 2022 | |
| Glaxosmithkline, LLC. | $16.09 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.49 | 2025 | Zoryve |
| Alexion Pharmaceuticals, INC. | $15.20 | 2019 | |
| Dexcom, INC. | $15.04 | 2022 | |
| Merck Sharp & Dohme LLC | $14.76 | 2025 | Gardasil 9, Vaxelis, M-M-R II |
| Biohaven Pharmaceuticals, INC. | $14.65 | 2021 | |
| Mylan Specialty L.P. | $14.51 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.75 | 2020 | |
| Clarus Therapeutics INC. | $9.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryce Warr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.